lansoprazole has been researched along with Liver Cirrhosis in 5 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of lansoprazole (L) after a single oral dose of 30 mg was determined in 18 healthy volunteers, 17 renal failure patients and 24 hepatic failure patients; 8 hepatitis and 16 with compensated (CC) or uncompensated (UCC) cirrhosis." | 3.68 | Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. ( Delhotal-Landes, B; Dellatolas, F; Duchier, J; Flouvat, B; Lemaire, M; Molinie, P, 1993) |
| "pylori infection in causation of minimal hepatic encephalopathy (MHE) has not been well studied." | 2.76 | Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. ( Agrawal, A; Chandra, M; Gupta, A; Koowar, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishi, T | 1 |
| Yamamoto, Y | 1 |
| Yamagishi, N | 1 |
| Iguchi, M | 1 |
| Tamai, H | 1 |
| Ito, T | 1 |
| Tsuruo, Y | 1 |
| Ichinose, M | 1 |
| Kitano, M | 1 |
| Ueyama, T | 1 |
| Tsai, CF | 1 |
| Chen, MH | 1 |
| Wang, YP | 1 |
| Chu, CJ | 1 |
| Huang, YH | 1 |
| Lin, HC | 1 |
| Hou, MC | 1 |
| Lee, FY | 1 |
| Su, TP | 1 |
| Lu, CL | 1 |
| Agrawal, A | 1 |
| Gupta, A | 1 |
| Chandra, M | 1 |
| Koowar, S | 1 |
| Delhotal-Landes, B | 1 |
| Flouvat, B | 1 |
| Duchier, J | 1 |
| Molinie, P | 1 |
| Dellatolas, F | 1 |
| Lemaire, M | 1 |
| Azuma, T | 1 |
| Ito, S | 1 |
| Suto, H | 1 |
| Ito, Y | 1 |
| Miyaji, H | 1 |
| Yamazaki, Y | 1 |
| Kato, T | 1 |
| Kuriyama, M | 1 |
2 trials available for lansoprazole and Liver Cirrhosis
| Article | Year |
|---|---|
Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Ammonia; Anti-Bacterial Agents; Clarithromycin; Drug | 2011 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromy | 2000 |
3 other studies available for lansoprazole and Liver Cirrhosis
| Article | Year |
|---|---|
Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats.
Topics: Animals; Aspartate Aminotransferases; Diet; Disease Models, Animal; Disease Progression; Heme Oxygen | 2018 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Contro | 2017 |
Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Aged; Female; Half | 1993 |